Global Transverse Myelitis Treatment Market , By Treatment Type (Intravenous Steroids, Plasma Exchange Therapy, Antiviral Medication, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Transverse Myelitis Treatment Market Analysis and Size
The global transverse myelitis treatment market is expected to witness significant growth during the forecast period. The factors propelled the growth of transverse myelitis treatment market are rise in cases of transverse myelitis treatment across the world and huge healthcare expenditure by the government. In addition, advances in the treatment options and well-established healthcare facilities are some of the impacting factors for the growth of eosinophil driven diseases market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global transverse myelitis treatment market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Transverse myelitis is a rare neurological disorder caused by spinal cord inflammation. The exact cause of transverse myelitis is idiopathic; however, it is assumed that abnormal immune cells start attacking the spinal cord, resulting in inflammation and damage of the tissues in the spinal cord.
Transverse Myelitis Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Type (Intravenous Steroids, Plasma Exchange Therapy, Antiviral Medication, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Zimmer Biomet (U.S.), Arthrex Inc. (U.S.), Terumo BCT Inc. (U.S.), Celling BioSciences Inc. (U.S.), APEX Biologix (U.S.), Juventix Regenerative Medical, LLC (Italy), Novartis AG (Switzerland), Fresenius Kabi AG (Germany), Akorn Incorporated (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Mylan N.V (U.S.), Johnsons & Johnsons Services Inc (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), Lilly (U.S.), Merck & Co., Inc. (U.S.), Aurobindo Pharma (India)
|
|
Market Opportunities
|
|
Global Transverse Myelitis Treatment Market Dynamics
Drivers
- Increasing Government Funding
Rise in government funding for several diagnostic procedures is likely to enhance the transverse myelitis treatment market. Several organizations are supporting the treatment of this disease globally namely the Academy of Spinal Cord Injury Professionals, Inc., Genetic and Rare Diseases (GARD) Information Center, the NIH/National Institute of Neurological Disorders and Stroke, and the Transverse Myelitis Association.
Opportunities
- Rising Demand of Multi-Dimensional Therapies
Methylprednisolone and dexamethasone are the common steroids that are used for the treatment of transverse myelitis. In addition, occupational and physical therapy have also been found to be effective in some patients. Also, chronic pain is found to be a common complication of transverse myelitis and as a result, doctors recommend common pain relievers such as naproxen, acetaminophen, ibuprofen. This factor boosts the opportunity of the transverse myelitis treatment market.
- Increasing Demand for Retail Pharmacies
The rise in the number of drugs for transverse myelitis delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Impending Drug Approvals
There are many drugs or injections that await for the approval of the drugs. Receiving approval for the drug from regulatory authorities is a very tedious and challenging task as regulatory authorities such as the U.S. FDA execute substantial and burdensome requirements upon companies involved in the clinical development, marketing, manufacturing, and distribution of drugs
- High Cost
The huge expenditure associated with these agents surely hamper the market growth.
This global transverse myelitis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global transverse myelitis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Transverse Myelitis Treatment Market Scope
The global transverse myelitis treatment market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Intravenous Steroids
- Plasma Exchange Therapy
- Antiviral Medication
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Transverse Myelitis Treatment Market Regional Analysis/Insights
The global transverse myelitis treatment market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global transverse myelitis treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global transverse myelitis treatment market throughout the forecasted period due to the increase government funding and awareness.
North America dominates the market due to the increase prevalence of transverse myelitis treatment and large availability of treatment options for patient suffering of transverse myelitis treatment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Transverse Myelitis Treatment Market Share Analysis
The global transverse myelitis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global transverse myelitis treatment market.
Key players operating in the global transverse myelitis treatment market include:
- Zimmer Biomet (U.S.)
- Arthrex Inc. (U.S.)
- Terumo BCT Inc. (U.S.)
- Celling BioSciences Inc. (U.S.)
- APEX Biologix (U.S.)
- Juventix Regenerative Medical, LLC (Italy)
- Novartis AG (Switzerland)
- Fresenius Kabi AG (Germany)
- Akorn Incorporated (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Mylan N.V (U.S.)
- Johnsons & Johnsons Services Inc (U.S.)
- F. Hoffman-La Roche Ltd. (Switzerland)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Aurobindo Pharma (India)
SKU-